Evolveimmune Therapeutics

Evolveimmune Therapeutics company information, Employees & Contact Information

Explore related pages

Evolveimmune Therapeutics email format Evolveimmune Therapeutics management contacts

Related company profiles:

EvolveImmune is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation. The EVOLVE platform tackles the treatment challenges of cancer cell resistance to current immunotherapies. The company’s lead internal drug candidate, EVOLVE104, will enter the clinic in 2025. We are based in Branford, CT.

Company Details

Employees
54
Founded
-
Address
Branford, Ct, Us
Phone
203-858-7389
Email
in****@****une.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
evolveimmune.com
Keywords
immunooncology, T-Cell exhaustion, immunobiologics.
HQ
Branford, CT
Competitors
RxSalesPros, Anavex Life Sciences, Synbio Technologies, Protara Therapeutics, CORXEL Pharmaceuticals, Halda Therapeutics, Nilo Therapeutics, InVitro Cell Research, LLC, Envisagenics, Princeton Biopartners.
Looking for a particular Evolveimmune Therapeutics employee's phone or email?

Evolveimmune Therapeutics Questions

News

Evolveimmune’s EVOLVE-104 gains IND clearance for solid tumors - BioWorld MedTech

Evolveimmune’s EVOLVE-104 gains IND clearance for solid tumors BioWorld MedTech

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics - PR Newswire

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics PR Newswire

EvolveImmune engages AbbVie | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

EvolveImmune engages AbbVie | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AbbVie and EvolveImmune Therapeutics sign oncology collaboration - Pharmaceutical Technology

AbbVie and EvolveImmune Therapeutics sign oncology collaboration Pharmaceutical Technology

AbbVie pays $65M, with $1.4B chaser, for options on EvolveImmune's T-cell engagers - Fierce Biotech

AbbVie pays $65M, with $1.4B chaser, for options on EvolveImmune's T-cell engagers Fierce Biotech

AbbVie taps T-cell engager tech from EvolveImmune to build next-gen cancer biologics - FirstWord Pharma

AbbVie taps T-cell engager tech from EvolveImmune to build next-gen cancer biologics FirstWord Pharma

AbbVie, EvolveImmune Therapeutics Strike Deal to Develop Biotherapeutics for Resistant Cancer Cells - Pharmaceutical Executive

AbbVie, EvolveImmune Therapeutics Strike Deal to Develop Biotherapeutics for Resistant Cancer Cells Pharmaceutical Executive

AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter

AbbVie inks up to $1.4 billion deal with EvolveImmune The Pharma Letter

The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics Session at SITC25 - Oncodaily

The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics Session at SITC25 Oncodaily

BioCT Names Dr. Stephen Bloch its 2023 Entrepreneur of the Year - Business Wire

BioCT Names Dr. Stephen Bloch its 2023 Entrepreneur of the Year Business Wire

AbbVie's multibillion-dollar collaboration targets new cancer therapy candidate - Crain's Chicago Business

AbbVie's multibillion-dollar collaboration targets new cancer therapy candidate Crain's Chicago Business

Evolveimmune snags another investor, inks $1.4B Abbvie deal - BioWorld MedTech

Evolveimmune snags another investor, inks $1.4B Abbvie deal BioWorld MedTech

Costimulatory bispecifics bring new biology to T cell engagers - BioCentury

Costimulatory bispecifics bring new biology to T cell engagers BioCentury

Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - CT Insider

Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio CT Insider

Industry vets launch biotech in Branford targeting cancer, autoimmune disease - Hartford Business Journal

Industry vets launch biotech in Branford targeting cancer, autoimmune disease Hartford Business Journal

AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal - Fierce Biotech

AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal Fierce Biotech

Abbvie and Simcere enter a $1B T-cell engager deal - BioWorld MedTech

Abbvie and Simcere enter a $1B T-cell engager deal BioWorld MedTech

How insects evolve immune-memory against bacterial infections - The Hindu

How insects evolve immune-memory against bacterial infections The Hindu

Companies like Evolveimmune Therapeutics

Envisagenics logo - Similar company to Evolveimmune Therapeutics

Envisagenics

57
RxSalesPros logo - Similar company to Evolveimmune Therapeutics

Rxsalespros

18
Anavex Life Sciences logo - Similar company to Evolveimmune Therapeutics

Anavex Life Sciences

45
Nilo Therapeutics logo - Similar company to Evolveimmune Therapeutics

Nilo Therapeutics

24
InVitro Cell Research, LLC logo - Similar company to Evolveimmune Therapeutics

Invitro Cell Researc...

35
Princeton Biopartners logo - Similar company to Evolveimmune Therapeutics

Princeton Biopartners

8
Protara Therapeutics logo - Similar company to Evolveimmune Therapeutics

Protara Therapeutics

47
CORXEL Pharmaceuticals logo - Similar company to Evolveimmune Therapeutics

Corxel Pharmaceuticals

47
Halda Therapeutics logo - Similar company to Evolveimmune Therapeutics

Halda Therapeutics

46
Synbio Technologies logo - Similar company to Evolveimmune Therapeutics

Synbio Technologies

23

Top Evolveimmune Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant